Voriconazole
- Generic Name
- Voriconazole
- Brand Names
- Vfend, Voriconazole Hikma (previously Voriconazole Hospira), Voriconazole Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N5O
- CAS Number
- 137234-62-9
- Unique Ingredient Identifier
- JFU09I87TR
- Background
Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha ...
- Indication
For the treatment of esophageal candidiasis, cadidemia, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.
- Associated Conditions
- Aspergillosis of the Central Nervous System, Aspergillosis of the Liver, Candidemia, Candidiasis, Coccidioidomycosis, Endocarditis caused by Aspergillus, Esophageal Candidiasis, Fungal Infections, Fungal meningitis caused by Exserohilum Infection, Fusarium infection, Histoplasmosis, Invasive Aspergillosis, Osteomyelitis caused by Aspergillus, Penicillium marneffei infection, Peritonitis caused by Aspergillus, Scedosporium Infection, Sinusitis aspergillus, Aspergillus endophthalmitis, Refractory Oral Candidiasis
- Associated Therapies
- -
Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2010-02-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT00620074
- Locations
- 🇺🇸
Pfizer Investigational Site, Fort Worth, Texas, United States
Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer
- Conditions
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 120
- Registration Number
- NCT00557362
- Locations
- 🇮🇳
Aravind Eye Hospital, Pondicherry, Tamil Nadu, India
A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT00556998
- Locations
- 🇺🇸
Pfizer Investigational Site, Houston, Texas, United States
This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis
- Conditions
- Interventions
- First Posted Date
- 2007-10-23
- Last Posted Date
- 2011-01-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 54
- Registration Number
- NCT00548262
- Locations
- 🇵🇦
Pfizer Investigational Site, Panama, Panama
Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 459
- Registration Number
- NCT00531479
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
Voriconazole as Prophylactic Therapy in Lung Transplant Recipients
- Conditions
- First Posted Date
- 2007-04-03
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 20
- Registration Number
- NCT00455364
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis
- Conditions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00423163
Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections
- Conditions
- Interventions
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT00418951
- Locations
- 🇺🇸
The University of Texas M D Anderson Cancer Center, Houston, Texas, United States
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
- Conditions
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 527
- Registration Number
- NCT00412893
- Locations
- 🇦🇷
Hospital Italiano de Buenos Aires, Ciudad Autonoma, Argentina
🇺🇸University of Alabama, Birmingham, Alabama, United States
🇺🇸University of Chicago, Division of Infectious Diseases, Chicago, Illinois, United States
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
- Conditions
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 450
- Registration Number
- NCT00413218
- Locations
- 🇺🇸
Idaho Falls Infectious Diseases PLLC, Idaho Falls, Idaho, United States
🇺🇸Somero Research Corporation, Palm Desert, California, United States
🇺🇸Loyola University Hospital, Maywood, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.